Literature DB >> 18073512

Cannabinoid system and neuroinflammation: implications for multiple sclerosis.

Fernando Correa1, Fabian Docagne, Leyre Mestre, Frida Loría, Miriam Hernangómez, José Borrell, Carmen Guaza.   

Abstract

There is a growing amount of evidence suggesting that cannabinoids may be neuroprotective in central nervous system inflammatory conditions. Advances in the understanding of the physiology and pharmacology of the cannabinoid system have potentiated the interest in cannabinoids as potential therapeutic targets. Here our aim was to update the actions of cannabinoids on immune system and glial cells and their implications on multiple sclerosis. We also show our results on the modulation of cytokines of the IL-12 family by cannabinoids in macrophages and brain microglia. We used murine primary cultures of macrophage and microglia activated by lipopolysaccharide/IFN-gamma and Theiler's virus to study the effects of cannabinoids on the regulation of IL-12 and IL-23 mRNA and protein IL-12p40, evaluated by RT-PCR and ELISA, respectively. Cannabinoids negatively regulate the production of these cytokines by microglial cells in part due to the activation of CB(2) receptors. The effects of cannabinoids on cytokine brain work and on the regulation of neuroinflammatory processes may affect chronic inflammatory demyelinating diseases such as multiple sclerosis. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18073512     DOI: 10.1159/000110644

Source DB:  PubMed          Journal:  Neuroimmunomodulation        ISSN: 1021-7401            Impact factor:   2.492


  9 in total

1.  Complementary and alternative medicine for the treatment of multiple sclerosis.

Authors:  Vijayshree Yadav; Lynne Shinto; Dennis Bourdette
Journal:  Expert Rev Clin Immunol       Date:  2010-05       Impact factor: 4.473

2.  Evaluation of the profiles of CB1 cannabinoid receptor signalling bias using joint kinetic modelling.

Authors:  Xiao Zhu; David B Finlay; Michelle Glass; Stephen B Duffull
Journal:  Br J Pharmacol       Date:  2020-05-15       Impact factor: 8.739

3.  Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS.

Authors:  Santhi Gorantla; Edward Makarov; Deepa Roy; Jennifer Finke-Dwyer; L Charles Murrin; Howard E Gendelman; Larisa Poluektova
Journal:  J Neuroimmune Pharmacol       Date:  2010-06-12       Impact factor: 4.147

4.  Real-time characterization of cannabinoid receptor 1 (CB1 ) allosteric modulators reveals novel mechanism of action.

Authors:  Erin E Cawston; William J Redmond; Courtney M Breen; Natasha L Grimsey; Mark Connor; Michelle Glass
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

Review 5.  Targeting Cannabinoid Signaling in the Immune System: "High"-ly Exciting Questions, Possibilities, and Challenges.

Authors:  Attila Oláh; Zoltán Szekanecz; Tamás Bíró
Journal:  Front Immunol       Date:  2017-11-10       Impact factor: 7.561

6.  Cannabinoids: A New Perspective on Epileptogenesis and Seizure Treatment in Early Life in Basic and Clinical Studies.

Authors:  Angélica Vega-García; Iris Feria-Romero; Anais García-Juárez; Ana Ch Munguia-Madera; Alexia V Montes-Aparicio; Esli Zequeida-Muñoz; Estefany Garcia-Albavera; Sandra Orozco-Suárez
Journal:  Front Behav Neurosci       Date:  2021-01-12       Impact factor: 3.558

Review 7.  Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review.

Authors:  Shaheen E Lakhan; Marie Rowland
Journal:  BMC Neurol       Date:  2009-12-04       Impact factor: 2.474

8.  Cannabinoids in the management of spasticity associated with multiple sclerosis.

Authors:  Anna Maria Malfitano; Maria Chiara Proto; Maurizio Bifulco
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

Review 9.  Endocannabinoid Receptors in the CNS: Potential Drug Targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders.

Authors:  José Antonio Estrada; Irazú Contreras
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.